PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE

被引：5
|
作者：
Delea, T. E. [1 ]
Sofrygin, O. [1 ]
Amonkar, M. [2 ]
机构：
[1] PAI, Brookline, MA USA
[2] GlaxoSmithKline Inc, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72194-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A43 / A44
页数：2
相关论文
共 50 条
  • [1] General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G)
    Brucker, PS
    Yost, K
    Cashy, J
    Webster, K
    Cella, D
    EVALUATION & THE HEALTH PROFESSIONS, 2005, 28 (02) : 192 - 211
  • [2] A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
    Sherrill, B.
    Amonkar, M.
    Sherif, B.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 275 - 275
  • [3] Estimation of patient preference-based utility weights from the functional assessment of cancer therapy - General
    Dobrez, Deborah
    Cella, David
    Pickard, A. Simon
    Lai, Jin-Shei
    Nickolov, Angel
    VALUE IN HEALTH, 2007, 10 (04) : 266 - 272
  • [4] Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
    Johnston, Stephen
    Pippen, John, Jr.
    Pivot, Xavier
    Lichinitser, Mikhail
    Sadeghi, Saeed
    Dieras, Veronique
    Gomez, Henry Leonidas
    Romieu, Gilles
    Manikhas, Alexey
    Kennedy, M. John
    Press, Michael F.
    Maltzman, Julie
    Florance, Allison
    O'Rourke, Lisa
    Oliva, Cristina
    Stein, Steven
    Pegram, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5538 - 5546
  • [5] Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer
    Schwarzberg, Lee S.
    Franco, Sandra X.
    Florance, Allison
    O'Rourke, Lisa
    Maltzman, Julie
    Johnston, Stephen
    ONCOLOGIST, 2010, 15 (02): : 122 - 129
  • [6] Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+metastatic breast cancer (MBC): A quality-of-life (QOL) analysis
    Sherif, B. N.
    Sherrill, B.
    Amonkar, M.
    Wu, Y.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G) (vol 28, pg 370, 2005)
    Brucker, PS
    Yost, K
    Cashy, J
    Webster, K
    Cella, D
    EVALUATION & THE HEALTH PROFESSIONS, 2005, 28 (03) : 370 - 370
  • [8] Validation of the functional assessment of cancer therapy-general (FACT-G) scale for measuring the health-related quality of life in Korean women with breast cancer
    Lee, EH
    Chun, M
    Kang, S
    Lee, HJ
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (07) : 393 - 399
  • [9] Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR plus ) metastatic breast cancer (MBC): first results from the EGF30008 Trial
    Johnston, S.
    Pegram, M.
    Press, M.
    Pippen, J.
    Pivot, X.
    Gomez, H.
    Florance, A.
    O'Rourke, L.
    Maltzman, J.
    CANCER RESEARCH, 2009, 69 (02) : 74S - 75S
  • [10] Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study
    Ro, J.
    Pippen, J.
    Pivot, X.
    Manikhas, A.
    Fehrenbacher, L.
    Makris, A.
    Florance, A.
    Maltzman, J.
    O'Rourke, L.
    Johnson, S.
    CANCER RESEARCH, 2009, 69 (24) : 796S - 797S
12345